Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Waste Management, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Waste Management, Inc. trades at $218.4 (market cap $84.67B). The key difference: Waste Management, Inc. is far larger — about 29.6× Dyne Therapeutics Inc. Common Stock's market cap, and Waste Management, Inc. pays a 1.78% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Waste Management, Inc. for 131 Days on average.
| DYN | WM | |
|---|---|---|
Market Cap | $2.86B | $84.67B |
Volume | 3,341,579 | 1,534,456 |
Sector | Health | Industrials |
52-Week High | $26.78 | $246.51 |
52-Week Low | $14.60 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $2.18B | $107.47B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
WM trades at $215.75, up 2.18% today, with a bullish technical signal despite mixed momentum indicators. The company reported strong revenue growth to $25.20 billion in 2025 and beat earnings estimates in two of the last three quarters. Analyst consensus is positive with 54% buy ratings, and the stock offers a dividend yield supported by robust cash flow from operations of $6.04 billion.
Outlook remains favorable due to pricing power and acquisition strategy, but elevated debt levels and a high P/E ratio of 29.96 pose risks. Near-term performance hinges on Q3 2026 earnings results expected on October 27, 2026, with investor focus on margin sustainability and debt management amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
